Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Art Vandelay AIA who wrote (2759)	5/14/1999 3:07:00 PM
From: quidditch	Read Replies (2) \| Respond to of 10280

Hey, Art. Whether costs of pushing through phase trials preparatory for an NDA, co-promotion or developing the sales force, this WILL result in a hit to cash over time. I have increased my position substantially over the past three weeks and am in for the LT. My nagging doubt is burn rate. I had asked the thread a while ago what the burn rate was, no one responded. With $500mm on hand at 12/31/98, less five months use, where do we get to before product sales/royalty revenues begin to amortize R&D, product development and G&A? Thanks and regards. Steven